JP2007523648A5 - - Google Patents

Download PDF

Info

Publication number
JP2007523648A5
JP2007523648A5 JP2006552376A JP2006552376A JP2007523648A5 JP 2007523648 A5 JP2007523648 A5 JP 2007523648A5 JP 2006552376 A JP2006552376 A JP 2006552376A JP 2006552376 A JP2006552376 A JP 2006552376A JP 2007523648 A5 JP2007523648 A5 JP 2007523648A5
Authority
JP
Japan
Prior art keywords
disease
type
derivative
end3 complementation
enzyme
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006552376A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007523648A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/004345 external-priority patent/WO2005077093A2/en
Publication of JP2007523648A publication Critical patent/JP2007523648A/ja
Publication of JP2007523648A5 publication Critical patent/JP2007523648A5/ja
Pending legal-status Critical Current

Links

JP2006552376A 2004-02-06 2005-02-07 高リン酸化リソソーム酵素製剤及びそれらの使用 Pending JP2007523648A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54258604P 2004-02-06 2004-02-06
PCT/US2005/004345 WO2005077093A2 (en) 2004-02-06 2005-02-07 Manufacture of highly phosphorylated lysosomal enzymes and uses thereof

Publications (2)

Publication Number Publication Date
JP2007523648A JP2007523648A (ja) 2007-08-23
JP2007523648A5 true JP2007523648A5 (cg-RX-API-DMAC7.html) 2008-03-27

Family

ID=34860323

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006552376A Pending JP2007523648A (ja) 2004-02-06 2005-02-07 高リン酸化リソソーム酵素製剤及びそれらの使用

Country Status (7)

Country Link
US (2) US20080014188A1 (cg-RX-API-DMAC7.html)
EP (1) EP1720405A4 (cg-RX-API-DMAC7.html)
JP (1) JP2007523648A (cg-RX-API-DMAC7.html)
AU (1) AU2005211775B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0507440A (cg-RX-API-DMAC7.html)
CA (1) CA2556245A1 (cg-RX-API-DMAC7.html)
WO (1) WO2005077093A2 (cg-RX-API-DMAC7.html)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7723296B2 (en) 2001-01-18 2010-05-25 Genzyme Corporation Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof
US7560424B2 (en) 2001-04-30 2009-07-14 Zystor Therapeutics, Inc. Targeted therapeutic proteins
WO2003057179A2 (en) 2002-01-11 2003-07-17 Biomarin Pharmaceutical, Inc. Use of p97 as an enzyme delivery system for the delivery of therapeutic lysosomal enzymes
JP5589165B2 (ja) 2003-01-31 2014-09-17 マウント シナイ スクール オブ メディシン オブ ニューヨーク ユニバーシティー タンパク質欠損性障害の治療のための併用療法
JP5137814B2 (ja) 2005-04-06 2013-02-06 ジェンザイム・コーポレーション 治療ターゲティングのための酸不安定リンカーを介するpegおよびポリシアルリソソーム酵素のコンジュゲート
EP3782655A1 (en) 2005-05-17 2021-02-24 Amicus Therapeutics, Inc. A method for the treatment of pompe disease using 1-deoxynojirimycin and derivatives
CN102978185B (zh) 2007-01-18 2015-02-11 建新公司 包含氨基氧基基团的寡糖及其轭合物
US8742079B2 (en) 2007-08-20 2014-06-03 Protalix Ltd. Saccharide-containing protein conjugates and uses thereof
PL3219795T3 (pl) * 2008-01-18 2024-09-16 Biomarin Pharmaceutical Inc. Wytwarzanie aktywnych wysoce fosforylowanych ludzkich enzymów sulfatazy lizosomalnej i ich zastosowania
US7722865B2 (en) 2008-01-18 2010-05-25 Biomarin Pharmaceutical Inc. Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof
WO2009131698A2 (en) * 2008-04-23 2009-10-29 Iowa State University Research Foundation, Inc. PHOSPHORYLATED RECOMBINANT N-ACETYL-alpha-D- GLUCOSAMINIDASE (NaGlu) AND USES THEREOF
WO2010056746A1 (en) * 2008-11-11 2010-05-20 Amicus Therapeutics, Inc. Therapy regimens, dosing regimens and stable medicaments for the treatment of pompe disease
EP3608330B1 (en) 2008-12-16 2022-11-09 Genzyme Corporation Synthetic intermediates for preparing oligosaccharide-protein conjugates
ES2919563T3 (es) * 2009-02-20 2022-07-27 Enhanx Biopharm Inc Sistema de administración de medicamentos a base de glutatión
CA2757645C (en) * 2009-04-06 2018-05-15 Mayo Foundation For Medical Education And Research Methods and materials for delivering molecules
US8785168B2 (en) 2009-06-17 2014-07-22 Biomarin Pharmaceutical Inc. Formulations for lysosomal enzymes
US9194011B2 (en) 2009-11-17 2015-11-24 Protalix Ltd. Stabilized alpha-galactosidase and uses thereof
CA2790786C (en) * 2010-02-24 2019-09-24 Zymenex A/S Process for production and purification of recombinant lysosomal alpha-mannosidase
WO2011108451A1 (ja) * 2010-03-01 2011-09-09 日本ケミカルリサーチ株式会社 遺伝子ノックアウト細胞を用いた組換え体リソソーム酵素の製造方法
JP6073783B2 (ja) 2010-06-25 2017-02-01 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド ヘパランn−スルファターゼのcns送達のための方法および組成物
CA2803166C (en) 2010-06-25 2023-03-07 Shire Human Genetic Therapies, Inc. Cns delivery of therapeutic agents
BR112012033214B1 (pt) 2010-06-25 2020-11-03 Shire Human Genetic Therapies, Inc. uso de uma formulação estável compreendendo uma proteína de iduronato-2-sulfatase (i2s), formulação compreendendo a mesma e recipiente
EP2588132A4 (en) * 2010-06-25 2014-10-15 Shire Human Genetic Therapies METHOD AND COMPOSITIONS FOR DELIVERING BETA GALACTOCEREBROSIDASE INTO THE CNS
JP6045493B2 (ja) 2010-06-25 2016-12-14 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド アリールスルファターゼaのcns送達の方法および組成物
KR20130043165A (ko) 2010-06-25 2013-04-29 샤이어 휴먼 지네틱 테라피즈 인크. 이듀로네이트-2-설파타제의 cns 전달을 위한 방법들 및 조성물들
US8956859B1 (en) 2010-08-13 2015-02-17 Aviex Technologies Llc Compositions and methods for determining successful immunization by one or more vaccines
EP2665814B1 (en) 2011-01-20 2017-05-17 Protalix Ltd. Nucleic acid construct for expression of alpha-galactosidase in plants and plant cells
US9138465B2 (en) 2011-04-28 2015-09-22 Osaka University Pharmaceutical composition for treating lysosomal storage disease
WO2012157136A1 (ja) * 2011-05-19 2012-11-22 財団法人東京都医学総合研究所 リン酸化糖鎖を含有する組換えヒトサポシンbタンパク質及びその用途
TW201307563A (zh) * 2011-05-19 2013-02-16 Shire Human Genetic Therapies 純化乙醯肝素-n-硫酸酯酶之方法
US9387236B2 (en) * 2011-06-10 2016-07-12 Prothera Inc. Pharmaceutical compositions containing protease and methods for the treatment of lysosomal storage diseases
AU2012278944B2 (en) 2011-07-05 2015-09-17 Bioasis Technologies Inc. p97-antibody conjugates and methods of use
CA2842492A1 (en) 2011-08-05 2013-02-14 Bioasis Technologies, Inc. P97 fragments with transfer activity
US20140377244A1 (en) 2011-12-23 2014-12-25 Shire Human Genetic Therapies, Inc. Stable formulations for cns delivery of arylsulfatase a
KR20200032244A (ko) 2012-03-07 2020-03-25 아미쿠스 세라퓨틱스, 인코포레이티드 폼페병의 치료를 위한 고농도 알파-글루코시다제 조성물
RS61598B1 (sr) 2012-05-03 2021-04-29 Amicus Therapeutics Inc Režimi doziranja za tretman pompeove bolesti
WO2014022515A1 (en) 2012-07-31 2014-02-06 Bioasis Technologies, Inc. Dephosphorylated lysosomal storage disease proteins and methods of use thereof
AU2013355046A1 (en) * 2012-12-07 2015-05-14 Shire Human Genetic Therapies, Inc. Methods and compositions for intrathecally administered treatment of mucupolysaccharidosis Type IIIA
NZ711373A (en) 2013-03-13 2020-07-31 Bioasis Technologies Inc Fragments of p97 and uses thereof
JP6603227B2 (ja) 2014-02-03 2019-11-06 バイオアシス テクノロジーズ インコーポレイテッド P97融合タンパク質
AU2015219339B2 (en) 2014-02-19 2020-03-05 Bioasis Technologies Inc. P97-IDS fusion proteins
CA2943890A1 (en) 2014-05-01 2015-11-05 Bioasis Technologies, Inc. P97-polynucleotide conjugates
JP6851964B2 (ja) 2014-09-30 2021-03-31 アミカス セラピューティックス インコーポレイテッド 炭水化物が増大している非常に強力な酸性アルファ−グルコシダーゼ
GB201508025D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Fabry disease gene therapy
IL299470B2 (en) * 2015-12-30 2026-05-01 Amicus Therapeutics Inc Improved acid alpha-glucosidase for the treatment of Pompe disease
CA3019354A1 (en) 2016-03-30 2017-10-05 Amicus Therapeutics, Inc. Method for selection of high m6p recombinant proteins
EP4793349A2 (en) * 2016-03-30 2026-08-19 Amicus Therapeutics, Inc. Method for selection of high m6p recombinant proteins
KR102618519B1 (ko) 2016-03-30 2023-12-28 아미쿠스 세라퓨틱스, 인코포레이티드 재조합 산 알파-글루코시다제를 포함하는 제형
EA039750B1 (ru) * 2017-03-30 2022-03-10 Амикус Терапьютикс, Инк. Способ отбора рекомбинантных белков с высоким содержанием m6p
CN119113091A (zh) 2017-05-15 2024-12-13 阿米库斯治疗学公司 重组人类酸性α-葡萄糖苷酶
AU2018281280B2 (en) 2017-06-07 2024-12-19 Regeneron Pharmaceuticals, Inc. Compositions and methods for internalizing enzymes
CN112040985A (zh) 2018-02-07 2020-12-04 瑞泽恩制药公司 用于递送治疗性蛋白质的方法和组合物
EP3793591A1 (en) 2018-05-17 2021-03-24 Regeneron Pharmaceuticals, Inc. Anti-cd63 antibodies, conjugates, and uses thereof
MX2022007399A (es) 2019-12-20 2022-09-19 Codexis Inc Variantes de alfa-glucosidasa ácida diseñadas.
JP2026522950A (ja) * 2023-06-30 2026-07-09 クロスウォーク セラピューティクス, インコーポレイテッド 操作された酸アルファ-グルコシダーゼバリアント

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4394448A (en) * 1978-02-24 1983-07-19 Szoka Jr Francis C Method of inserting DNA into living cells
US4391904A (en) 1979-12-26 1983-07-05 Syva Company Test strip kits in immunoassays and compositions therein
US5186941A (en) 1983-05-06 1993-02-16 Vestar, Inc. Vesicle formulation for the controlled release of therapeutic agents
TW492882B (en) 1997-11-28 2002-07-01 Caleb Pharmaceuticals Inc Cholinergic antagonist plaster composition
US6534300B1 (en) * 1999-09-14 2003-03-18 Genzyme Glycobiology Research Institute, Inc. Methods for producing highly phosphorylated lysosomal hydrolases
US6261595B1 (en) * 2000-02-29 2001-07-17 Zars, Inc. Transdermal drug patch with attached pocket for controlled heating device

Similar Documents

Publication Publication Date Title
US7241442B2 (en) Method for producing proteins suitable for treating lysosomal storage disorders
US8580922B2 (en) Peptide linkers for polypeptide compositions and methods for using same
US8841322B2 (en) Method for increasing the activity of lysosomal enzymes
Fürst et al. Activator proteins and topology of lysosomal sphingolipid catabolism
JP5990102B2 (ja) ホスホ−6−マンノースへのマンノース−1−ホスホ−6−マンノース結合の加水分解
JP2016037504A5 (cg-RX-API-DMAC7.html)
JP2022046524A (ja) 治療学的酵素類の結合体
CN101855232A (zh) 植物培养物中高甘露糖蛋白的生产
US20090022702A1 (en) Methods for introducing mannose 6-phosphate and other oligosacharides onto glycoproteins
BR112013007616A2 (pt) Manosidades capazes de desopercular ("uncap") ligações manose-1-fosfo-6-manose e desmanosilar n-glicanos fosforilados e métodos para facilitar a captação celular por mamíferos de glicoproteínas
JP2007523648A (ja) 高リン酸化リソソーム酵素製剤及びそれらの使用
JP2013539974A5 (cg-RX-API-DMAC7.html)
AU2019202865B2 (en) Peptide linkers for polypeptide compositions and methods for using same
Pohl et al. Glycosylation-and phosphorylation-dependent intracellular transport of lysosomal hydrolases
JP7791517B2 (ja) ライソゾームを標的とした新規ddsの開発
Greiner-Tollersrud et al. Lysosomal storage disorders
Wisselaar et al. Effects of N-hydroxyethyl-1-deoxynojirimycin (BAY m 1099) on the activity of neutral-and acid α-glucosidases in human fibroblasts and HepG2 cells
US20090263371A1 (en) Use Polysaccharides for Promotion of Enzymatic Activity
WO2022145449A1 (ja) ライソゾームを標的とした新規ddsの開発
Hancock et al. Lysosomal degradation of glycoproteins and glycosaminoglycans
Eto et al. Various sulfatase activities in leukocytes and cultured skin fibroblasts from heterozygotes for the multiple sulfatase deficiency (mukosulfatidosis)
Wiesmann Disorders of Lysosomal Enzymes: General Considerations
Halley Release and uptake of lysosomal enzymes: studied in cultured cells
Sayut et al. Enzyme replacement therapy for lysosomal storage disorders
Marchase et al. Glucose phosphotransferase and intracelular trafficking